Endothelin‐1 is independently associated with 180‐day mortality after adjusting for body mass index

Pérez, Antonio L.; Tang, W.H. Wilson

doi:10.1002/ejhf.550

Cited by 1 publication

(1 citation statement)

References 5 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[366][367][368][369][370] Similarly, circulating ET-1 levels are evolving as predictors of clinical outcome and survival in patients with acute heart failure as well. [371][372][373] Whether the ET-1 propeptides endothelin-like domain peptide (ELDP) and CT-pro-ET-1, which are increased in patients with HFrEF, 39 have diagnostic or prognostic clinical value remains to be shown.…”

Section: Heart Failure With Reduced Ejection Fraction (Hfref)mentioning

confidence: 99%

Endothelin: 30 Years From Discovery to Therapy

2019

View full text Add to dashboard Cite

Discovered in 1987 as a potent endothelial cell–derived vasoconstrictor peptide, endothelin-1 (ET-1), the predominant member of the endothelin peptide family, is now recognized as a multifunctional peptide with cytokine-like activity contributing to almost all aspects of physiology and cell function. More than 30 000 scientific articles on endothelin were published over the past 3 decades, leading to the development and subsequent regulatory approval of a new class of therapeutics—the endothelin receptor antagonists (ERAs). This article reviews the history of the discovery of endothelin and its role in genetics, physiology, and disease. Here, we summarize the main clinical trials using ERAs and discuss the role of endothelin in cardiovascular diseases such as arterial hypertension, preecclampsia, coronary atherosclerosis, myocardial infarction in the absence of obstructive coronary artery disease (MINOCA) caused by spontaneous coronary artery dissection (SCAD), Takotsubo syndrome, and heart failure. We also discuss how endothelins contributes to diabetic kidney disease and focal segmental glomerulosclerosis, pulmonary arterial hypertension, as well as cancer, immune disorders, and allograft rejection (which all involve ET A autoantibodies), and neurological diseases. The application of ERAs, dual endothelin receptor/angiotensin receptor antagonists (DARAs), selective ET B agonists, novel biologics such as receptor-targeting antibodies, or immunization against ET A receptors holds the potential to slow the progression or even reverse chronic noncommunicable diseases. Future clinical studies will show whether targeting endothelin receptors can prevent or reduce disability from disease and improve clinical outcome, quality of life, and survival in patients.

show abstract